These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24023757)

  • 21. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential benefit of statin prescription based on prediction of treatment responsiveness in older individuals: an application to the PROSPER randomized controlled trial.
    Nguyen TL; Trompet S; Brodersen JB; Hoogland J; Debray TPA; Sattar N; Jukema JW; Westendorp RGJ
    Eur J Prev Cardiol; 2024 Jun; 31(8):945-953. PubMed ID: 38085032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease).
    White HD; Tonkin A; Simes J; Stewart R; Mann K; Thompson P; Colquhoun D; West M; Nestel P; Sullivan D; Keech AC; Hunt D; Blankenberg S;
    J Am Coll Cardiol; 2014 Feb; 63(4):345-54. PubMed ID: 24140630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
    N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk.
    Shepherd J; Blauw GJ; Murphy MB; Cobbe SM; Bollen EL; Buckley BM; Ford I; Jukema JW; Hyland M; Gaw A; Lagaay AM; Perry IJ; Macfarlane PW; Meinders AE; Sweeney BJ; Packard CJ; Westendorp RG; Twomey C; Stott DJ
    Am J Cardiol; 1999 Nov; 84(10):1192-7. PubMed ID: 10569329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
    Maitland-van der Zee AH; Boerwinkle E; Arnett DK; Davis BR; Leiendecker-Foster C; Miller MB; Klungel OH; Ford CE; Eckfeldt JH
    Am Heart J; 2007 Jan; 153(1):54-8. PubMed ID: 17174637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).
    Deedwania P; Stone PH; Bairey Merz CN; Cosin-Aguilar J; Koylan N; Luo D; Ouyang P; Piotrowicz R; Schenck-Gustafsson K; Sellier P; Stein JH; Thompson PL; Tzivoni D
    Circulation; 2007 Feb; 115(6):700-7. PubMed ID: 17283260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Packard CJ; Ford I; Robertson M; Shepherd J; Blauw GJ; Murphy MB; Bollen EL; Buckley BM; Cobbe SM; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG;
    Circulation; 2005 Nov; 112(20):3058-65. PubMed ID: 16275871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Freeman DJ; Robertson M; Brown EA; Rumley A; Tobias ES; Frölich M; Slagboom PE; Jukema JW; de Craen AJ; Sattar N; Ford I; Gaw A; Greer IA; Lowe GD; Stott DJ
    BMC Geriatr; 2011 Feb; 11():8. PubMed ID: 21342490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The PROSPER Study (PROspective study of pravastatin in the elderly at risk)].
    Kulbertus H; Scheen AJ
    Rev Med Liege; 2002 Dec; 57(12):809-13. PubMed ID: 12632840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis.
    Ford I; Bezlyak V; Stott DJ; Sattar N; Packard CJ; Perry I; Buckley BM; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J
    PLoS Med; 2009 Jan; 6(1):e16. PubMed ID: 19166266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial.
    Matthan NR; Resteghini N; Robertson M; Ford I; Shepherd J; Packard C; Buckley BM; Jukema JW; Lichtenstein AH; Schaefer EJ;
    J Lipid Res; 2010 Jan; 51(1):202-9. PubMed ID: 19578163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.
    Rahman M; Baimbridge C; Davis BR; Barzilay JI; Basile JN; Henriquez MA; Huml A; Kopyt N; Louis GT; Pressel SL; Rosendorff C; Sastrasinh S; Stanford C;
    Clin Nephrol; 2013 Oct; 80(4):235-48. PubMed ID: 23816477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statin therapy in the elderly: does it make good clinical and economic sense?
    Mungall MM; Gaw A; Shepherd J
    Drugs Aging; 2003; 20(4):263-75. PubMed ID: 12641482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lessons learned from the prospective pravastatin pooling project.
    Byington RP; Sacks FM
    Curr Atheroscler Rep; 2004 Sep; 6(5):366-74. PubMed ID: 15296703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators.
    Marschner IC; Colquhoun D; Simes RJ; Glasziou P; Harris P; Singh BB; Friedlander D; White H; Thompson P; Tonkin A;
    J Am Coll Cardiol; 2001 Jul; 38(1):56-63. PubMed ID: 11451296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pravastatin: a review of its use in elderly patients.
    Bang LM; Goa KL
    Drugs Aging; 2003; 20(14):1061-82. PubMed ID: 14651445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
    Simes RJ; Marschner IC; Hunt D; Colquhoun D; Sullivan D; Stewart RA; Hague W; Keech A; Thompson P; White H; Shaw J; Tonkin A;
    Circulation; 2002 Mar; 105(10):1162-9. PubMed ID: 11889008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
    Simes J; Furberg CD; Braunwald E; Davis BR; Ford I; Tonkin A; Shepherd J
    Eur Heart J; 2002 Feb; 23(3):207-15. PubMed ID: 11792135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.